Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Ipsen announced that it has entered into a definitive agreement to acquire global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE® (irinotecan…
Read More...
Read More...